These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 14556007

  • 41. A yeast two-hybrid system reconstituting substrate recognition of the von Hippel-Lindau tumor suppressor protein.
    Bex C, Knauth K, Dambacher S, Buchberger A.
    Nucleic Acids Res; 2007; 35(21):e142. PubMed ID: 17986458
    [Abstract] [Full Text] [Related]

  • 42. pVHL-independent ubiquitination of HIF1alpha and its stabilization by cobalt ion.
    Kanaya K, Kamitani T.
    Biochem Biophys Res Commun; 2003 Jul 04; 306(3):750-5. PubMed ID: 12810083
    [Abstract] [Full Text] [Related]

  • 43. Vhlh gene deletion induces Hif-1-mediated cell death in thymocytes.
    Biju MP, Neumann AK, Bensinger SJ, Johnson RS, Turka LA, Haase VH.
    Mol Cell Biol; 2004 Oct 04; 24(20):9038-47. PubMed ID: 15456877
    [Abstract] [Full Text] [Related]

  • 44. Activation of hypoxia-induced transcription in normoxia.
    Hägg M, Wennström S.
    Exp Cell Res; 2005 May 15; 306(1):180-91. PubMed ID: 15878343
    [Abstract] [Full Text] [Related]

  • 45. VHL takes HIF's breath away.
    Krek W.
    Nat Cell Biol; 2000 Jul 15; 2(7):E121-3. PubMed ID: 10878820
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumor suppressor gene product.
    Tsuchiya H, Iseda T, Hino O.
    Cancer Res; 1996 Jul 01; 56(13):2881-5. PubMed ID: 8674032
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. Hypoxia-inducible factor underlies von Hippel-Lindau disease stigmata.
    Ohh M, Taber CC, Ferens FG, Tarade D.
    Elife; 2022 Aug 30; 11():. PubMed ID: 36040300
    [Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma.
    Sufan RI, Jewett MA, Ohh M.
    Am J Physiol Renal Physiol; 2004 Jul 30; 287(1):F1-6. PubMed ID: 15180922
    [Abstract] [Full Text] [Related]

  • 56. Regression of solid tumors by engineered overexpression of von Hippel-Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1alpha.
    Sun X, Kanwar JR, Leung E, Vale M, Krissansen GW.
    Gene Ther; 2003 Dec 30; 10(25):2081-9. PubMed ID: 14595381
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. VHL mutations linked to type 2C von Hippel-Lindau disease cause extensive structural perturbations in pVHL.
    Knauth K, Cartwright E, Freund S, Bycroft M, Buchberger A.
    J Biol Chem; 2009 Apr 17; 284(16):10514-22. PubMed ID: 19228690
    [Abstract] [Full Text] [Related]

  • 59. The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer.
    Kim W, Kaelin WG.
    Curr Opin Genet Dev; 2003 Feb 17; 13(1):55-60. PubMed ID: 12573436
    [Abstract] [Full Text] [Related]

  • 60. USP9X destabilizes pVHL and promotes cell proliferation.
    Zhang C, Peng Z, Zhu M, Wang P, Du X, Li X, Liu Y, Jin Y, McNutt MA, Yin Y.
    Oncotarget; 2016 Sep 13; 7(37):60519-60534. PubMed ID: 27517496
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.